Literature DB >> 7831532

Mammographically-detected ductal in situ carcinoma of the breast analyzed with a new classification. A study of 127 cases: correlation with estrogen and progesterone receptors, p53 and c-erbB-2 proteins, and proliferative activity.

B Zafrani1, A Leroyer, A Fourquet, M Laurent, D Trophilme, P Validire, X Sastre-Garau.   

Abstract

The new histologic classification proposed by Holland et al was applied to 127 cases of mammographically-detected ductal carcinoma in situ (DCIS). The relationship between histologic types and tumor cell expression of estrogen and progesterone receptors, p53 protein, c-erbB-2 oncoprotein, and proliferative activity markers was evaluated. There were 38 (30%) well differentiated, 39 (31%) intermediately differentiated and 50 (39%) poorly differentiated DCIS. Immunohistochemistry showed that 81% of the tumors were estrogen-receptor positive and 73% progesterone receptor positive. p53 protein and c-erbB-2 oncoprotein expression was identified in 40% and 57% of the cases, respectively. Growth-fraction determination with the Ki-67 antibody showed that 52% of the tumors had high proliferative activity. A highly significant association was found between the histologic types of DCIS and p53 protein, c-erB-b2 oncoprotein, and proliferative activity marker expression: these biological markers were more frequently overexpressed in less differentiated DCIS. No significant relationship with estrogen or progesterone receptor expression was noted. A strong relationship with the amount of tumor necrosis was also found. The clinical significance of these results should, however, be determined by long-term follow-up studies of patients with DCIS.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7831532

Source DB:  PubMed          Journal:  Semin Diagn Pathol        ISSN: 0740-2570            Impact factor:   3.464


  22 in total

1.  Multicentric Breast Carcinoma: Evaluation of Clinicopathological and Immunohistochemical Characteristics.

Authors: 
Journal:  Breast Cancer       Date:  1996-12-20       Impact factor: 4.239

Review 2.  Molecular analysis of premalignant and carcinoma in situ lesions of the human breast.

Authors:  P S Steeg; S E Clare; J A Lawrence; Q Zhou
Journal:  Am J Pathol       Date:  1996-09       Impact factor: 4.307

3.  C-Erb-b2 oncogene expression in intraductal proliferative lesions of the breast.

Authors:  Filiz Eren; Zerrin Calay; Haydar Durak; Bülent Eren; Nil Comunoğlu; Ovgü Aydin
Journal:  Bosn J Basic Med Sci       Date:  2012-02       Impact factor: 3.363

4.  [Prognostic factors in ductal carcinoma in situ].

Authors:  A Lebeau
Journal:  Pathologe       Date:  2006-09       Impact factor: 1.011

5.  Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast.

Authors:  C C Wykoff; N Beasley; P H Watson; L Campo; S K Chia; R English; J Pastorek; W S Sly; P Ratcliffe; A L Harris
Journal:  Am J Pathol       Date:  2001-03       Impact factor: 4.307

6.  Androgen receptor expression in ductal carcinoma in situ of the breast: relation to oestrogen and progesterone receptors.

Authors:  A G A Selim; G El-Ayat; C A Wells
Journal:  J Clin Pathol       Date:  2002-01       Impact factor: 3.411

7.  p53 mutations and expression in breast carcinoma in situ.

Authors:  J Lukas; N Niu; M F Press
Journal:  Am J Pathol       Date:  2000-01       Impact factor: 4.307

8.  Vascularity demonstrated by Doppler ultrasound and immunohistochemistry in invasive ductal carcinoma of the breast.

Authors:  E E Sterns; S SenGupta; F Saunders; B Zee
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

Review 9.  Is DCIS breast cancer, and how do I treat it?

Authors:  N Bijker; M Donker; J Wesseling; G J den Heeten; E J Th Rutgers
Journal:  Curr Treat Options Oncol       Date:  2013-03

Review 10.  Biological features of premalignant disease in the human breast.

Authors:  D C Allred; S K Mohsin
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-10       Impact factor: 2.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.